INVENT experiences increased orders and broadens their portfolio in the global market
For INVENT Umwelt- und Verfahrenstechnik AG, 2023 continued to grow in all areas. The company, which is dedicated to the…
Newsrooms
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
Immatics Announces Full Year 2022 Financial Results and Corporate Update
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target…
Immatics Announces Third Quarter 2022 Financial Results and Business Update
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective res…
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in…
Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME
IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging funct…
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and develop…
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billio…
Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update
ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201…